Search

Objective: To report the incidence of and evaluate demographic, ocular comorbidities, and intraoperative factors for rhegmatogenous retinal detachment (RRD) and retinal tear (RT) after cataract surgery in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Design: Retrospective cohort study. Participants: Patients aged ≥ 40 years who underwent cataract surgery between 2014 and 2017. Methods: Multivariable logistic regression was used to evaluate demographic, comorbidity, and intraoperative factors associated with RRD and RT after cataract surgery. Main Outcome Measures: Incidence and risk factors for RRD or RT within 1 year of cataract surgery. Results: Of the 3 177 195 eyes of 1 983 712 patients included, 6690 (0.21%) developed RRD and 5489 (0.17%) developed RT without RRD within 1 year after cataract surgery. Multivariable logistic regression odds ratios (ORs) showed increased risk of RRD and RT, respectively, among men (OR 3.15; 95% confidence interval [CI], 2.99–3.32; P < 0.001 and 1.79; 95% CI, 1.70–1.89; P < 0.001), and younger ages compared with patients aged > 70, peaking at age 40 to 50 for RRD (8.61; 95% CI, 7.74–9.58; P < 0.001) and age 50 to 60 for RT (2.74; 95% CI, 2.52–2.98; P < 0.001). Increased odds of RRD were observed for procedure eyes with lattice degeneration (LD) (10.53; 95% CI, 9.82–11.28; P < 0.001), hypermature cataract (1.61; 95% CI, 1.06–2.45; P = 0.03), complex cataract surgery (1.52; 95% CI, 1.4–1.66; P < 0.001), posterior vitreous detachment (PVD) (1.24; 95% CI, 1.15–1.34; P < 0.001), and high myopia (1.2; 95% CI, 1.14–1.27; P < 0.001). Lattice degeneration conferred the highest odds of RT (43.86; 95% CI, 41.39–46.49; P < 0.001). Conclusion: In the IRIS Registry, RRD occurs in approximately 1 in 500 cataract surgeries in patients aged > 40 years within 1 year of surgery. The presence of LD conferred the highest odds for RRD and RT after surgery. Additional risk factors for RRD included male gender, younger age, hypermature cataract, PVD, and high myopia. These data may be useful during the informed consent process for cataract surgery and help identify patients at a higher risk of retinal complications. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Purpose To assess how resident and attending ophthalmologists perceive and evaluate ethically controversial scenarios regarding mentorship, authorship, and ethics compliance that may occur during research involving residents.

Background In 2017, the Accreditation Council for Graduate Medical Education announced all ophthalmology residency programs would provide a combined transitional or joint preliminary program for first postgraduate year (PGY-1) residents, with mandatory implementation by 2023.

Objective Ophthalmology residency programs aim to improve resident surgical teaching through increased surgical exposure over a 4-year period. Resident-centric surgical clinics across various surgical specialties have been established to help develop surgical autonomy and experience. We present the first demonstration of a resident-centric chalazion incision and drainage clinic (chalazion clinic) in an ophthalmology residency with the goal of increasing early surgical exposure to residents. Design The chalazion clinic was founded in July 2019. It is a once weekly procedure clinic conducted by an ophthalmology resident and supervised by an ophthalmology attending. Patients with chalazia were referred directly to this clinic for evaluation and management, rather than the oculoplastics clinic as they were in the past. Retrospective review of Accreditation Council for Graduate Medical Education (ACGME) case logs of all residents per academic year before and after establishment of the chalazion clinic was performed in order to assess the impact on residents' chalazion procedures numbers per academic year. Setting The study involved a single academic ophthalmology department. Participants Ophthalmology residents of all years were present. Results A resident of any year performed an average of 3.0 chalazion procedures per year in the 2018 to 2019 academic year, 3.8 in 2019 to 2020, and 8.4 in the 2020 to 2021, which represents a 180% increase in procedure numbers per resident. Among post-graduate-year 2s (PGY)2s, the average number of chalazion procedures increased from 2.1 procedure per year to 22.3 per year (961.9% increase). Conclusion To the best of our knowledge, this is the first description of a dedicated resident-centric chalazion clinic in an ophthalmology residency program. PGY2s demonstrated the largest increase in procedural numbers. While chalazion incision and drainage is a minor procedure, increased exposure to surgical procedures early in training could help improve residents' skills and confidence. This clinic provides a proof of concept of a dedicated minor procedure clinic for ophthalmology residents to increase early procedural volume.

Purpose: This study examined how treatment patterns for proliferative diabetic retinopathy (PDR) have changed over time using clinical registry data from the AAO IRIS® Registry (Intelligent Research in Sight). Design: A retrospective cohort analysis using the IRIS Registry database spanning 2013–2017. Participants: A total of 141 317 patients with newly diagnosed PDR (International Classification of Diseases [ICD], Tenth Revision, codes E08.35, E09.35, E10.35, E11.35, and E13.35 and ICD, Ninth Revision, code 362.02) were included. Methods: Comparison analyses were conducted using Tukey and chi-square tests, and time-trend analyses were conducted using Mann-Kendall tests and Theil-Sen slopes. Main Outcome Measures: Patient characteristics including age, gender, and laterality; whether patients received intravitreal anti–vascular endothelial growth factor injections (IVI) only, panretinal photocoagulation (PRP) only, both IVI and PRP (IVI+PRP), or observation; intravitreal drug data; and diabetic macular edema (DME) status were compared. Results: From 2013–2017, the average age of PDR diagnosis was 59.2 years, with 53.3% of patients being male. Sixty-two thousand one hundred five newly diagnosed PDR patients (43.9%) received IVI, 32 293 patients (27.1%) received PRP, 27 664 patients (19.6%) received IVI+PRP, and 13 255 patients (9.4%) underwent observation. In 2013, more PDR patients undergoing treatment received PRP only (47.5%) than IVI only (37.3%) or IVI+PRP (15.1%). From 2013 to 2017, the percentage of patients treated with PRP only decreased by 5.6% per year (P = 0.05) and the percentage of patients treated with IVI only increased by 3.9% per year (P = 0.05). By 2017, most patients received IVI only (52.9%). Patients with PDR with DME were more likely than patients without DME to receive IVI only (64.3% vs. 31.5%; P < 0.001). Among patients receiving IVI and IVI+PRP, bevacizumab (69.8%) was the most common intravitreal medication given followed by aflibercept (18.4%) then ranibizumab (11.7%). Conclusions: In this cohort analysis of the IRIS Registry, IVI surpassed PRP as the more common method of treating newly diagnosed PDR from 2013 to 2017, with bevacizumab administered in more than two thirds of IVIs.